ID
11638
Description
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Lien
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Mots-clés
Versions (2)
- 24/11/2011 24/11/2011 -
- 09/07/2015 09/07/2015 - Martin Dugas
Téléchargé le
9 juillet 2015
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Psoriasis NCT00216879
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Description
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Type de données
boolean
Alias
- UMLS CUI-1
- C0853073
- UMLS CUI-2
- C0018233
Description
UVB therapy anywhere on the patient within 14 days prior to randomisation
Type de données
boolean
Alias
- UMLS CUI-1
- C0564461
Description
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Type de données
boolean
Alias
- UMLS CUI-1
- C0005522
Description
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Type de données
boolean
Alias
- UMLS CUI-1
- C1515119
Description
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Type de données
boolean
Alias
- UMLS CUI-1
- C0150349
Description
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Type de données
boolean
Alias
- UMLS CUI-1
- C0150349
- UMLS CUI-2
- C0001617
Description
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Type de données
boolean
Alias
- UMLS CUI-1
- C2347852
Description
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Type de données
boolean
Alias
- UMLS CUI-1
- C0343052
- UMLS CUI-2
- C0152081
- UMLS CUI-3
- C0748052
Description
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Type de données
boolean
Alias
- UMLS CUI-1
- C0037278
Description
Known or suspected severe renal insufficiency or severe hepatic disorders
Type de données
boolean
Alias
- UMLS CUI-1
- C1565489
- UMLS CUI-2
- C1869009
Description
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Type de données
boolean
Alias
- UMLS CUI-1
- C0020437
Description
Trial subjects should be using an adequate method of contraception
Type de données
boolean
Alias
- UMLS CUI-1
- C0700589
Similar models
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
C0018233 (UMLS CUI-2)
C0001617 (UMLS CUI-2)
C0152081 (UMLS CUI-2)
C0748052 (UMLS CUI-3)
C1869009 (UMLS CUI-2)